Comparison of the patterns of altered cerebral glucose utilisation produced by competitive and non-competitive NMDA receptor antagonists

Brain Research

Volumn 735, Issue 1, 1996, Pages 67-82

  Sharkey, J ^a   Ritchie, I M ^a   Butcher, S P ^a   Kelly, J S ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cerebral glucose metabolism; CGS190755; FR115427; MK801; NMDA receptor

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; DEOXYGLUCOSE; DIZOCILPINE; FR 115427; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BRAIN REGION; CONTROLLED STUDY; GLUCOSE UTILIZATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030607197     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00574-4     Document Type: Article

References (36)

1. [1] Bullock, R. and Fujisawa, H., The role of glutamate antagonists for the treatment of CNS injury, J. Neurotrauma, 9 (1992) s443-s462.
2. [2] Chapman, A.G., Graham, J.L., Swan, J.H. and Meldrum, B.S., Regional glucose utilisation in rat brain following the administration of CGP39551, a competitive NMDA antagonist, J. Cereb. Blood Flow Metab., 11 (Suppl. 2) (1991) s226.
3. [3] Clineschmidt, B.V., Martin, G.E. and Bunting, P.R., Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-54H-dibenzo [a,d]cyclohepten-5,10-imine (MK801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties, Drug Dev. Res., 2 (1982) 123-134.
4. [4] Clow, D.W., Lee, S.J. and Hammer, R.P., Competitive (AP-7) and non-competitive (MK-801) NMDA receptor antagonists differentially alter glucose utilization in rat cortex, Synapse, 7 (1991) 260-268.
5. [5] Collingridge, G.L. and Watkins, J.C. In G.L. Collingridge and J.C. Watkins (Eds.), The NMDA Receptor, IRL Press, Oxford, 1994.
6. [6] Crosby, G., Crane, A.M. and Sokoloff, L., Local changes in cerebral glucose utilization during ketamine anaesthesia, Anaesthesiology, 56 (1982) 437-443.
7. [7] Cudennec, A., Duverger, D., Lloyd, K.G., MacKenzie, E.T., McCulloch, J., Motohashi, N., Nishikawa, T. and Scatton, B., Effects of the GABA receptor agonist, progabide, upon local cerebral glucose utilization, Brain Res., 423 (1987) 162-172.
8. [8] Grotta, J.C., Picone, C.M., Ostrow, P.T., Strong, R.A., Earls, R.M., Yao, L.P., Rhoades, H.M. and Dedman, J.R., CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia, Ann. Neurol., 27 (1990), 612-619.
9. [9] Halliwell, R.F., Peters, J.A. and Lambert, J.J., The mechanism of action and pharmacological specificity of the anticonvulsant NMDA antagonist, MK801: a voltage clamp study on neuronal cells in culture, Br. J. Pharmacol., 96 (1989) 480-494.
10. [10] Hodgkiss, P., Sherriffs, H.J., Cottrell, D.A., Shirakawa, K., Kelly, J.S., Kuno, A., Ohkubo, M., Butcher, S.P. and Olverman, H.J., Neurochemical and electrophysiological studies on FR115427, a novel non-competitive NMDA receptor antagonist, Eur. J. Pharmacol., 240 (1993) 219-227.
11. [11] Hogan, M.J., Gjedde, A. and Hakim, A.M., In vivo distribution of CGS19755 within brain in a model of focal cerebral ischemia, J. Neurochem., 58 (1992) 186-191.
12. [12] Jane, D.E., Olverman, H.J. and Watkins, J.C., Agonists and competitive: structure-activity and molecular modelling studies. In G.L. Collingridge and J.C. Watkins (Eds.), The NMDA Receptor, IRL Press, Oxford, 1984.
13. [13] Katsuta, K., Nakanishi, H., Shirakawa, K., Yoshida, K., Takagi, K., Tamura, A., The neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427 in focal cerebral ischaemia in rats, J. Cereb. Blood Flow Metab., 15 (1995) 345-348.
14. [14] Kelly, P.A.T., Ford, I. and McCulloch, J., The effect of diazepam upon local cerebral glucose use in the conscious rat, Neuroscience, 19 (1986) 257-265.
15. [15] Kurumaji, A., Nehls, D.G., Park, C.K. and McCulloch, J., Effects of the NMDA antagonists, MK801 and CPP upon local cerebral glucose use, Brain Res., 496 (1989) 268-284.
16. [16] Lehmann, J., Hutchison, A.J., McPherson, S.E., Mondadori, C., Schmutz, M., Sinton, C.M., Tsai, C., Murphy, D.E., Steel, D.J., Williams, M., Cheney, D.L. and Wood, P.L., CGS19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist, J. Pharmacol. Exp. Ther., 246 (1988) 65-75.
17. [17] Lodge, D. and Johnson, K.M., Non-competitive excitatory amino acid antagonists, Trends Pharmacol. Sci., 11 (1990) 81-86.
18. [18] MacDonald, J.F. and Nowak, L.M., Mechanism of blockade of excitatory amino acid receptor channels, Trends Pharmacol. Sci., 11 (1990) 167-172.
19. [19] McCulloch, J., Bullock, R. and Teasdale, G.M., Excitatory amino acid antagonists: opportunities for the treatment of ischaemic brain damage in man. In B.S. Meldrum (Ed.), Excitatory Amino Acid Antagonists, Blackwell, 1991.
20. [20] McCulloch, J. and Iversen, L.L., Autoradiographic assessment of the effects of N-methyl-D-asparate receptor antagonists in vivo, Neurochem. Res., 16 (1991) 951-963.
21. [21] Meibach, R.C., Glick, S.D., Cox, R. and Maayani, S., Localisation of phencyclidine-induced changes in brain energy metabolism, Nature, 282 (1979) 625-626.
22. [22] Nakanishi, H., Katsuta, K., Koide, T., Shirakawa, K. and Yoshida, K., Protective effect of FR115427 against ischemic hippocampal damage in gerbils, Jpn. J. Pharmacol., 64 (1994) 189-193.
23. [23] Nehls, D.G., Kurumaji, A., Park, C.K., MacCormack, A.G. and McCulloch, J., The effects of N-methyl-D-aspartate receptor blockade upon the relationship between local cerebral blood flow and glucose utilisation, Brain Res., 511 (1990) 271-279.
24. [24] Nelson, S.R., Howard, R.B., Cross, R.S. and Samson, R., Ketamine-induced changes in regional glucose utilisation in the rat brain, Anaesthesiology, 52 (1980) 330-334.
25. [25] Oguchi, K,, Arakawa, K., Nelson, S.R. and Samson, F., The influence of droperidol, diazepam and physostigmine on ketamine-induced behavior and regional glucose utilisation in the rat, Anaesthesiology, 57 (1982) 353-358.
26. [26] Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M. and Sesma, M.A., NMDA antagonist neurotoxicity: mechanism and prevention, Science, 254 (1991) 1515-1518.
27. [27] Olverman, H.J. and Watkins, J.C., NMDA agonists and competitive. In J.C. Watkins and G.L. Collingridge (Eds.), The NMDA Receptor, IRL Press, Oxford, 1989.
28. [28] Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, London, 1986.
29. 3H]-FR115427, a novel, non-competitive NMDA receptor antagonist, to rat brain membranes, Eur. J. Pharmacol., 247 (1993) 319-324.
30. [30] Simon, R. and Shiraishi, K., N-Methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism, Ann. Neurol., 27 (1990) 606-611.
31. 14C]-deoxyglucose method for the measurement of local cerebral glucose utilisation: theory, procedure, and normal values in the conscious and anaesthetized albino rat, J. Neurochem., 28 (1977) 897-916.
32. [32] Swan, J.H. and Meldrum, B.S., Protection by NMDA antagonist against cell loss following transient ischaemia, J. Cereb. Blood Flow Metab., 10 (1990) 343-351.
33. [33] Weissman, A.D., Dam, M. and London, E.D., Alterations in local cerebral glucose utilisation induced by phencyclidine, Brain Res., 435 (1987) 29-40.
34. [34] Wong, E.H.F. and Kemp, J.A., Sites for antagonism on the N-methyl-D-aspartate receptor channel complex, Annu. Rev. Pharmacol. Toxicol., 31 (1991) 401-425.
35. [35] Wong, E.H.F., Kemp, J.A., Priestly, T., Knight, A.R., Woodruff, G.N. and Iversen, L.L., The anticonvulsant MK801 is a potent N-methyl-D-aspartate antagonist, Proc. Natl Acad. Sci. USA, 83 (1986) 7104-7108.
36. 3H]MK801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes, J. Neurochem., 50 (1988) 274-281.